Diego Sanchez and Optimal Blue’s VP of product management explore lender retention strategies, market trends and more.

Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular ...

Researchers found “no significant discrepancy in safety events” between trastuzumab biosimilars and the originator product.